[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasmacytoma-of-bone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasmacytoma-of-bone":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100601835","phase-2-radiation-combined-with-bcmacd3-bispecific-antibody-therapy-for-solitary-bone-plasmacytoma-with-mild-bone-marrow-infiltration-100601835",false,"NCT07115667","Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically confirmed SBP with \\\u003C10% clonal plasma cells in marrow\n* ECOG ≤ 2\n* No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.\n* Meets laboratory and imaging criteria\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.\n2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","ALL","18 Years","78 Years",{"count":20,"type":21},21,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.",[27,28,29],"Solitary Bone Plasmacytoma","Plasmacytoma of Bone","Plasma Cell Disorders",[31,32],"solitary bone plasmacytoma","BCMA\u002FCD3 bispecific antibody","RECRUITING","2025-09-05",{"date":36,"type":37},"2025-09-08","ACTUAL",{"date":39,"type":37},"2025-08-25",{"date":41,"type":21},"2027-12-01",{"name":43,"class":44},"Institute of Hematology & Blood Diseases Hospital, China","OTHER"]